If You Invested in Nika Pharmaceuticals (NIKA)

Nika Pharmaceuticals, Inc. (NIKA) is a healthcare company in the pharmaceutical sector, focused on drug development and manufacturing within the drug manufacturers – specialty and generic industry. According to its public disclosures, the company concentrates on therapies where strengthened cell immunity plays a central role, with a particular emphasis on serious and chronic diseases.

Nika Pharmaceuticals states that it specializes in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and other conditions for which enhanced immune response is considered vital. The company reports that its intellectual property portfolio includes six drugs in injection form, four drugs in tablet form, and eleven dietary supplements. Two of the injectable drugs are described as having successfully undergone clinical trials with positive treatment results, and the company positions these assets as the foundation for its therapeutic pipeline.

The company also highlights a broader corporate goal that combines commercial objectives with access to care. Nika Pharmaceuticals states that it aims not only to achieve corporate profits but also to provide better and easier access to life‑saving medicinal drugs and useful dietary supplements. This dual focus on economic outcomes and availability of treatment is presented as a key part of its business philosophy.

In its public communications, Nika Pharmaceuticals describes plans related to pharmaceutical manufacturing capacity. Through its subsidiary Nika Europe, Ltd., the company has outlined the development of a pharmaceutical factory designed to comply with Good Manufacturing Practice (GMP) standards. Disclosures describe this facility as a "building within a building" concept, with specialized systems such as water for injections (WFI) and advanced HVAC infrastructure intended to support sterile production conditions. Nika Europe has reported progress on the technical project for this factory and on securing and testing production line equipment for injectable drugs.

Nika Pharmaceuticals has also presented a broader business strategy that includes the construction of three types of pharmaceutical facilities: one for drugs in injection form, one for drugs in tablet form, and one for dietary supplements. In connection with these plans, the company has disclosed that it became the beneficial owner of a production building and land in Sofia Province, Bulgaria, through its ownership of Nika Europe, Ltd. The building is described as having multiple manufacturing halls and an office section, with infrastructure such as an electrical substation and systems intended to support future laboratory and manufacturing operations.

In addition to its focus on immune‑related therapies, Nika Pharmaceuticals reports activity in the generic drugs segment. The company has disclosed the purchase of technologies and full registration dossiers for the production of generic forms of VINPOCETINE 10mg, MENTHYL VALERATE 60mg, METAMIZOLE SODIUM 500mg, and later a dossier for GALANTAMINE HYDROBROMIDE 5mg, which is described as being used in the treatment of forms of dementia. These acquisitions are presented as part of a strategy to build a portfolio that addresses common and significant diseases.

Nika Pharmaceuticals also reports that it has eleven dietary supplements in its portfolio. In its disclosures, the company notes that six of these products—Physiolong, Carotilen, Hypocholestin, Biodetoxin, Anthocylen C, and Silymaron—have shown useful properties and are already on the market in Bulgaria. The company has stated that it is working to expand distribution of these supplements more widely, including within the European Union, Asia, and Africa, while it continues to develop its broader pharmaceutical capabilities.

A central element of Nika Pharmaceuticals’ strategy is the development and commercialization of ITV‑1, a treatment for AIDS described as based on the Inactivated Pepsin Fraction (IPF). The company reports that a clinical trial on AIDS patients conducted by Immunotech Laboratories BG, which holds exclusive rights for production and distribution of ITV‑1, has shown positive treatment results. Nika Pharmaceuticals has entered into a Joint Business Agreement with Immunotech Laboratories BG with the stated goal of combining efforts to realize the registration, production, and distribution of medicinal products based on IPF.

The company has also published a report on the therapeutic effect and potential economic impact of ITV‑1, describing its findings on volunteers suffering from AIDS, cancer, and other diseases. In that context, Nika Pharmaceuticals has highlighted examples of what it characterizes as curative effects and a wider applicability of ITV‑1 beyond AIDS. The company further notes that ITV‑1 has shown compatibility with other drugs used in the treatment of AIDS and refers to its wide‑spectrum antiretroviral action as a basis for potential use in other viral‑based diseases.

On the commercial side, Nika Pharmaceuticals has disclosed a series of exclusive distribution agreements for the ITV‑1 treatment for AIDS. The company reports that it has signed agreements granting partners exclusive distribution rights in the United Arab Emirates (UAE), Ukraine, Iraq, Jordan, and Syria. It has also announced a distribution agreement for the Republic of Nigeria with I.Conntact‑Connect Limited, following negotiations that concluded on June 11, 2024. Public statements describe Nigeria as a key market, and Nika Pharmaceuticals has indicated that it is preparing to open a satellite office there to serve as a hub for the West Africa region.

In its communications about these agreements, the company has presented revenue projections based on the pricing of ITV‑1 treatment sets under the distribution terms. It has also framed these arrangements in humanitarian terms, citing the prevalence of HIV and challenges in access to treatment in markets such as Nigeria, Ukraine, and parts of the Middle East and North Africa. Nika Pharmaceuticals has linked its commercial plans with an expressed mission to provide better and more affordable life‑saving drugs to patients who might otherwise lack access.

Through these disclosed activities—development of immune‑focused therapies, acquisition of generic drug dossiers, expansion of dietary supplement offerings, construction of GMP‑compliant manufacturing facilities, and distribution agreements in multiple territories—Nika Pharmaceuticals presents itself as building a vertically integrated pharmaceutical project. The company’s public statements emphasize both the potential financial outcomes of its strategy and its goal of improving access to medicinal products and dietary supplements for patients facing serious diseases.